Freenome (NASDAQ:FRNM) Rating Increased to Strong-Buy at Guggenheim

Freenome (NASDAQ:FRNM) was upgraded by analysts at Guggenheim to a “strong-buy” rating in a report issued on Thursday,Zacks.com reports.

A number of other equities research analysts also recently weighed in on the company. Jefferies Financial Group started coverage on Freenome in a report on Monday. They issued a “buy” rating and a $17.00 price target for the company. TD Cowen initiated coverage on Freenome in a research note on Tuesday. They set a “buy” rating and a $17.00 price objective on the stock. BTIG Research began coverage on shares of Freenome in a report on Monday. They issued a “buy” rating and a $17.00 price objective for the company. Finally, Leerink Partners initiated coverage on shares of Freenome in a research note on Friday, August 14th. They set an “outperform” rating and a $18.00 target price for the company. Two equities research analysts have rated the stock with a Strong Buy rating and three have given a Buy rating to the company’s stock. According to data from MarketBeat, Freenome presently has a consensus rating of “Buy” and a consensus price target of $18.00.

Freenome Price Performance

NASDAQ:FRNM opened at $13.51 on Thursday. Freenome has a 52 week low of $9.97 and a 52 week high of $14.26.

Freenome Company Profile

Freenome is a biotechnology company developing blood-based tests designed to detect cancer at earlier, more treatable stages. The company combines artificial intelligence with multiomics analysis, examining biological signals in blood—including genetic, immune and other molecular indicators—to identify cancer-related patterns.

Freenome’s research and development efforts have focused on noninvasive screening for colorectal cancer, with additional programs targeting other cancers. Its platform is intended to support earlier detection and may also have applications in cancer monitoring and treatment-related decision-making.

Founded in 2014 and based in California, Freenome has pursued collaborations with healthcare and biopharmaceutical organizations to advance its testing technology.